ReproCELL Announced: A Joint Development with the National Cancer Center

YOKOHAMA, Japan

ReproCELL, Inc. (JASDAQ:4978):

“ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to go on sale in December this year. Read on for details.

Our company, in conjunction with the National Cancer Center, has successfully developed and commercialized a culture fluid that allows for the cultivation of human primary liver cells, outside of the body, while retaining high levels of functionality. The preservation of liver functions (CYP: enzymatic functions involved in counteraction and metabolism in livers) outside of the body has been technically difficult until now. Rethinking the composition of culture fluids from scratch, our product allows for a preservation of liver functionality many times greater than products previously available.

Current liver cell cultivation fluids are widely used throughout the world, in the pharmaceutical industry’s drug discovery processes, for their toxic values. Our group aims to entirely replace existing products with our product, which can preserve liver functionality at a high level, through our global sales network.

Additionally, at the ISSX (International Society for the Study of Xenobiotics: an international scientific society at the cutting edge in the field of liver and small intestine research) meeting held on October 18^th of this year we delivered a technological presentation about the development of our product, which also received high praise from a scholarly perspective. Hereafter, the great technological strength we have fostered through the commercialization of this product will help massively boost our company’s competitiveness in the field of iPS cell-related products — our primary industry — and will also be proactively put to use in the field of regenerative medicine.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151224005080/en/